fenofibrate / Generic mfg. - LARVOL DELTA

Evaluation of 18 S rRNA as an endogenous control in OpenArray® plasma RNA qPCR workflows. (PubMed, Mol Biol Rep) - "18 S rRNA is a stable technical control in plasma OpenArray® workflows and did not measurably bias co-amplified targets during pre-amplification. Archived and new primer pools showed only minor systematic differences and remained broadly comparable at the group level."

Journal • Diabetes • Metabolic Disorders

LOW-DOSE FENOFIBRATE 200 MG EVERY OTHER DAY VERSUS STANDARD-DOSE FENOFIBRATE 200 MG/DAY AS SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS PATIENTS WITH INSUFFICIENT RESPONSE: A PROPENSITY SCORE ANALYSIS (UEGW 2026) - "Introduction: Fenofibrate is often used as a second-line treatment for patients with primary biliary cholangitis (PBC) who have poor ursodeoxycholic acid (UDCA) efficacy, but its optimal dose and safety have not been clarified. Low-dose fenofibrate (200 mg QOD), a second-line treatment for PBC patients with a poor response to UDCA, was as effective as the standard dose (200 mg QD) and showed an outstanding safety profile. Further validation in prospective, multicentre clinical trials is needed."

Clinical • Hepatology • Immunology • Primary Biliary Cholangitis

Oxidative Stress as a Pathophysiological Core of Obesity: Preclinical Evidence for Antioxidant-Based Therapy Strategies. (PubMed, Pharmaceuticals (Basel)) - "This review synthesizes preclinical evidence for diverse interventions, including vitamins A, B, C, E, and D; minerals such as zinc and selenium; amino acids such as N-acetylcysteine (NAC), L-carnitine, and taurine; various antioxidant compounds; and approved drugs including metformin, exenatide, fenofibrate, and orlistat. Despite differing structures and mechanisms, these interventions converge on restoring redox balance by activating nuclear factor erythroid 2-related factor 2 (Nrf2)/AMP-activated protein kinase (AMPK), increasing glutathione, and stabilizing mitochondria. However, translation of these preclinical findings into clinical practice requires further clarification of dosing, delivery methods, and long-term safety."

Journal • Preclinical • Review • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • AMPK • CAT

Association Between the Triglyceride-to-HDL Cholesterol Ratio and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Real-World Retrospective Study. (PubMed, Biomedicines) - "The association between the TG/HDL-C ratio and glycemic control was assessed using group comparisons, Spearman correlation, tertile analysis, and multivariable logistic regression adjusted for age, sex, LDL-C, total cholesterol, insulin use, statin use, and fenofibrate use...However, its standalone discriminatory performance is modest. Given its modest discriminatory performance, the TG/HDL-C ratio should not be considered a standalone diagnostic or predictive tool for poor glycemic control; rather, it may serve as an accessible adjunctive metabolic marker associated with an adverse glycemic and lipid profile."

Journal • Real-world evidence • Retrospective data • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Causal Relationship Between Psoriatic Arthritis and Coronary Heart Disease: A Mendelian Randomization and Bioinformatics Analysis. (PubMed, Psoriasis (Auckl)) - "The drug prediction analysis indicated that prednisone, tretinoin, fumaric acid, adenosine, fenofibrate, and herbal medicines including Salvia miltiorrhiza Bunge, Conioselinum anthriscoides "Chuanxiong", Achyranthes bidentata Blume, along with herbal ingredients like kaempferol and naringenin, might treat the comorbidities. The predicted drugs and herbs can become candidate targets for subsequent research. Due to the limitations of the European population and the limited sample size of public transcriptome data, our findings require further external validation."

Causal relationship • Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • BCL2A1 • LY96

The Triple Threat: New-Onset Type 2 Diabetes, Severe Diabetic Ketoacidosis, and Hypertriglyceridemia-Induced Pancreatitis (ACG 2026) - "He was successfully transitioned to subcutaneous insulin and started on fenofibrate...Given that HTGP can be more severe than other forms of pancreatitis, clinicians must maintain a high index of suspicion for the "Triple Threat" in patients presenting with new-onset DKA. Figure: Figure 1"

Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus • LPL

Cholestatic Liver Disease Secondary to Novel ABCB4 and ABCC2 Mutations Responds to Ursodiol and Fenofibrate Therapy (ACG 2026) - "After 12 months of therapy, laboratory parameters improved to TB 0.7, AST 59, ALT 117, and AP 306. UDCA is a bile acid and works by increasing the solubility of bile contents. Fenofibrate through its activation of peroxisome proliferator-activated receptor alpha (PPARa) has been shown to increase the transcription of ABCB4."

Cholestasis • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure • ABCB1 • ABCB4 • ABCC2 • ER • PPARA

PPARα Activation Attenuates Right Ventricular Hypertrophy by Regulating Myocardial Glucose and Lipid Metabolism in High-Altitude Pulmonary Hypertension In Vivo and In Vitro. (PubMed, High Alt Med Biol) - "In this study, our findings demonstrate that PPARα exerts a protective effect against RVH, at least in part, by promoting fatty acid oxidation through upregulation of its downstream target proteins CPT-1 and acyl-CoA oxidase 1."

Journal • Preclinical • Cardiovascular • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • ACOX1 • PPARA

Effect of systemic fibrates on diabetic retinopathy prevention and progression: A comprehensive systematic review and meta-analysis. (PubMed, Surv Ophthalmol) - "Adjusted estimates from non-randomized studies were directionally consistent. These findings support a stage-specific role for fenofibrate in patients with established diabetic retinopathy, particularly to reduce progression to diabetic macular edema, while the evidence for primary prevention remains inconclusive."

Journal • Retrospective data • Review • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Real-World Long-Term Safety of Statin-Fibrate Combination Therapy in Older Patients (≥75 Years): A European Cohort Analysis. (PubMed, Geriatrics (Basel)) - " This real-life observational post hoc subgroup analysis suggests that in patients aged 75 years and older with mixed dyslipidemia at high or very high CV risk, pravastatin 40 mg/fenofibrate 160 mg demonstrates an acceptable long-term safety profile. The combination offers additional TG lowering and HDL-C improvement beyond moderate-intensity statin monotherapy, without a significant increase in overall safety events over three years."

Journal • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Gastroenterology • Hepatology • Hypertension • Metabolic Disorders • Mixed Hyperlipidemia • Musculoskeletal Diseases • Pancreatitis • Rheumatology

Potential Protective Effects of Mitochondria-Related Gene EHHADH on Diabetic Cardiomyopathy. (PubMed, Cell Biol Int) - "After adding Fenofibrate(FNB), apoptosis proteins were detected by western blot...FNB promoted EHHADH expression, thereby reducing apoptosis, lipid accumulation, and mitochondrial damage in myocardial cells. EHHADH exerts a protective effect in DCM by reducing mitochondrial damage, oxidative stress, lipid accumulation, and cardiomyocyte apoptosis."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Metabolic Disorders • EHHADH

SAFE Study: Serine and Fenofibrate Study in Patients With MacTel Type 2 (clinicaltrials.gov) - P2 | N=89 | Completed | Sponsor: The Lowy Medical Research Institute Limited | Active, not recruiting ➔ Completed | N=60 ➔ 89

Enrollment change • Trial completion • Ophthalmology

Indices of obesity, malnutrition and inflammation are strong predictors of mortality in adults with type 2 diabetes: the FIELD study. (PubMed, Diabetologia) - "MVX independently predicts total and cardiovascular mortality in type 2 diabetes, offering prognostic value beyond traditional risk factors. The absolute event rates reflect the treatment standards of the FIELD recruitment period (1997-2000), prior to widespread use of several contemporary cardioprotective therapies. The results support further investigation of the clinical utility of MVX for determination of personalised risk."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Oncology • Sarcopenia • Type 2 Diabetes Mellitus

Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review. (PubMed, Nephron) - "Setmelanotide promoted clinically meaningful weight loss and improved liver, kidney, and metabolic parameters in an adult patient carrying BBS10-likely pathogenic variants. Together with emerging evidence for interventional studies, these findings suggest that MC4R agonism may confer organ-level and cardiometabolic benefits beyond weight reduction."

Journal • Real-world evidence • Bardet–Biedl Syndrome • Dyslipidemia • Genetic Disorders • Hepatology • Hypertriglyceridemia • Inherited Retinal Dystrophy • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Ophthalmology • Renal Disease • MC4R

Preparation and Characterization of Fenofibric Acid-Loaded Electrospun Fibrous Mats. (PubMed, Nanomaterials (Basel)) - "In vitro dissolution tests in artificial saliva showed a markedly enhanced release rate of fenofibric acid from the fibrous mats compared with the pure crystalline form, indicating a significant improvement in apparent solubility. These findings highlight the potential of PVP-based electrospun fiber formulation as an efficient carrier for the active metabolite of fenofibrate."

Journal

Pregnancy Outcomes Following Maternal Fenofibrate Exposure. (PubMed, Congenit Anom (Kyoto)) - "Therefore, the observed stillbirths may be related to underlying maternal disease rather than fenofibrate exposure. Overall, the findings of this case series do not suggest a clear teratogenic signal associated with maternal fenofibrate exposure during pregnancy."

Journal • Retrospective data • Autism Spectrum Disorder • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia

Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability? (PubMed, AAPS J) - "Loperamide hydrochloride, fenofibrate, compound c0 (a drug candidate) and carvedilol were chosen for this study as poorly water-soluble model compounds. Although solubilities and dissolution profiles of the model compounds were mostly improved by the binders, correlation between solubility in buffers and dissolution from the tablets in biorelevant FaSSIF-V1 was poor, indicating that dissolution experiments may be a better screening tool than solubility experiments. An important conclusion of these studies is that it is possible to increase the rate, and in some cases, the extent of dissolution of four poorly soluble drugs using wet granulation with polymeric binders, followed by tablet compression - a simple and cost-effective approach to improving drug performance."

Journal

Association of Common Anti-Inflammatory Medications with Reduced Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes. (PubMed, Ophthalmology) - "Cetirizine, ibuprofen, and prednisone were associated with reduced incidence of DME and PDR in adults with T2DM, with effect sizes comparable to those of the fenofibrate positive control. These findings support prospective evaluation of anti-inflammatory medications for the prevention of vision-threatening diabetic retinopathy."

Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms. (PubMed, J Pharm Pharm Sci) - "Emerging experimental ocular delivery strategies may improve local bioavailability while reducing systemic exposure. Overall, fenofibrate represents a biologically plausible adjunctive ophthalmic therapy, but further randomized trials, mechanistic studies, pharmacokinetic evaluation, and long-term safety assessments are required to define its therapeutic role beyond diabetic retinopathy."

Journal • Review • Age-related Macular Degeneration • Diabetes • Diabetic Macular Edema • Diabetic Neuropathy • Diabetic Retinopathy • Dry Eye Disease • Dyslipidemia • Macular Degeneration • Metabolic Disorders • Ophthalmology • Pain • Retinal Disorders • Thermal Injury • Wet Age-related Macular Degeneration • PPARA

Subclinical Hyperthyroidism Due to Graves’ Disease and a Large Mixed Hyperfunctioning Nodule: An Atypical Case of Marine-Lenhart Syndrome (ETA 2026) - "She was under metformin, fenofibrate, magnesium, cholecalciferol, and escitalopram...Methimazole 2.5mg once daily was initiated... MLS should be considered in patients with nodular goiter and biochemical hyperthyroidism, even when hormone excess is mild. Careful integration of ultrasound findings, immunological markers, and scintigraphy is essential for accurate diagnosis and optimal management."

Clinical • CNS Disorders • Depression • Dyslipidemia • Endocrine Disorders • Grave’s Disease • Idiopathic Arthritis • Immunology • Lipodystrophy • Metabolic Disorders • Polyendocrine Metabolic Ovarian Syndrome

Fenofibrate Protects Against Antipsychotic-Induced Hyperglycemia Through Weight Loss and FGF21 Dependent Mechanisms. (PubMed, FASEB J) - "Fenofibrate attenuated both OLZ-induced hyperlipidemia and increases in whole-body fatty acid oxidation, with the latter effects being dependent upon FGF21. Together, our findings demonstrate that fenofibrate protects against acute olanzapine-induced hyperglycemia and hyperlipidemia in a weight loss and FGF21-dependent manner."

Journal • CNS Disorders • Diabetes • Dyslipidemia • Metabolic Disorders • FGF21

Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence. (PubMed, J Clin Endocrinol Metab) - "Fenofibrate use was associated with a reduced risk of STDR in individuals with T2D in the real-world clinical practice. These fundings suggest that fenofibrate could be considered as a DR preventive therapy for individuals with T2D."

HEOR • Journal • Real-world evidence • Diabetes • Diabetic Retinopathy • Dyslipidemia • Metabolic Disorders • Retinal Disorders • Type 2 Diabetes Mellitus

Effect of fenofibrate on diabetic retinopathy progression: an RCT-Only systematic review and meta-analysis incorporating the LENS trial. (PubMed, Diabetes Res Clin Pract) - "Venous thromboembolism was increased (RR 1.52, 1.12-2.06), an estimate derived entirely from FIELD (103/4,755 vs 68/4,767). In adults with diabetes, predominantly type 2, fenofibrate slows structural DR progression but is not established as vision-preserving."

Journal • Retrospective data • Review • Cardiovascular • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus • Venous Thromboembolism

Indices of obesity, malnutrition and inflammation are strong predictors of mortality in adults with type 2 diabetes: the FIELD study (EASD 2026) - "Materials and In 9,550 adults with T2D followed for 5 years in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, the composite index MVX (metabolic vulnerability), and its components IVX (inflammation vulnerability) and MMX (metabolic malnutrition) were derived from baseline plasma NMR... Inflammation, malnutrition and sarcopenia, measured by MVX, independently predicts all-cause, cardiovascular and cancer mortality in T2D over 5 years, offering strong prognostic value beyond traditional risk factors. Absolute event rates reflect the treatment standards of the FIELD recruitment period (1997-2000), prior to widespread use of several contemporary cardioprotective therapies. Results support further investigation of its clinical utility for personalised risk."

Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Lower socioeconomic status is associated with attenuated triglyceride-rich lipoprotein response to fenofibrate: a FIELD trial substudy (EASD 2026) - "Fine-grained area-level SES captures modest but reproducible variation in triglyceride-rich lipoprotein response to fenofibrate, even within a controlled trial environment with standardised drug exposure and monitoring. These findings suggest that granular SES provides incremental information beyond conventional clinical risk factors and warrants consideration in predictive and risk-stratification frameworks addressing health equity-related variation in cardiometabolic phenotype."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus